WO2025241452 - AN ANTIBODY-DRUG CONJUGATE CONTAINING AN EXTRA FUNCTIONAL COMPOUND FOR ENHANCED TREATMENT OF REFRACTORY DISEASES

National phase entry is expected:
Publication Number WO/2025/241452
Publication Date 27.11.2025
International Application No. PCT/CN2024/133750
International Filing Date 22.11.2024
Title **
[English] AN ANTIBODY-DRUG CONJUGATE CONTAINING AN EXTRA FUNCTIONAL COMPOUND FOR ENHANCED TREATMENT OF REFRACTORY DISEASES
[French] CONJUGUÉ ANTICORPS-MÉDICAMENT CONTENANT UN COMPOSÉ FONCTIONNEL SUPPLÉMENTAIRE POUR LE TRAITEMENT AMÉLIORÉ DE MALADIES RÉFRACTAIRES
Applicants **
HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD
HANGZHOU DAC BIOTECH CO., LTD
Inventors
ZHAO, Robert Yongxin
YANG, Qingliang
HUANG, Yuanyuan
YE, Hangbo
LIU, Xiaolei
ZHANG, Lingli
LI, Weibin
GUO, Huihui
YE, Zhicang
WANG, Junpeng
XIE, Xiaoqiang
LUO, Yi
WANG, Juan
ZHAO, Ziyu
Priority Data
PCT/CN2024/094651   22.05.2024   CN
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
Number of Office Actions *
*
International Searching Authority
*
Recordal of a Change of the Applicant's Name/Address
*
Type of Assignment
*
Applicant's Legal Status
*
*
*
*
*
*
Entry into National Phase under
*
Patent Delivery
*
Translation

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing, Examination, Granting9581
EPO Filing, Examination, Granting34833
Japan Filing, Examination, Granting2422
South Korea Filing, Examination, Granting2638
USA Filing, Examination, Granting14340
MasterCard Visa
Total: 63,814
Contact Us
Abstract[English] An antibody-drug conjugate containing a side chain of a functional small molecule for enhancement of targeted treatment of cancers and refractory diseases is provided. The preparation of such conjugate, pharmaceutical compositions, and methods in treatment of refractory diseases are also provided.[French] L'invention concerne un conjugué anticorps-médicament contenant une chaîne latérale d'une petite molécule fonctionnelle pour l'amélioration du traitement ciblé de cancers et de maladies réfractaires. L'invention concerne également la préparation d'un tel conjugué, des compositions pharmaceutiques et des méthodes de traitement de maladies réfractaires.

Rejoining the server...